Ignite Creation Date:
2024-05-05 @ 5:03 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00371683
Status:
COMPLETED
Last Update Posted:
2015-12-30
First Post:
2006-08-30
Brief Title:
Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
A Phase 3 Randomized Double-Blind Active-Controlled Enoxaparin Parallel-Group Multi-Center Study to Evaluate the Safety and Efficacy of Oral Apixaban in Subjects Undergoing Elective Total Knee Replacement Surgery
Status:
COMPLETED
Status Verified Date:
2015-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to learn if apixaban can prevent blood clots in the leg deep vein Thrombosis DVT and lung pulmonary embolism PE that sometimes occur after knee replacement surgery and to learn how apixaban compares to enoxaparin Lovenox for preventing these clots The safety of apixaban will also be studied
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None